SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 4.81 |
| Enterprise Value ($M) | -2.18 |
| Book Value ($M) | 11.78 |
| Book Value / Share | 2.20 |
| Price / Book | 0.41 |
| NCAV ($M) | -3.39 |
| NCAV / Share | -0.63 |
| Price / NCAV | -1.42 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.28 |
| Return on Assets (ROA) | -0.24 |
| Return on Equity (ROE) | -0.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.22 |
| Current Ratio | 0.22 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.96 |
| Assets | 16.13 |
| Liabilities | 4.35 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -3.94 |
| Net Income | -4.27 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -1.19 |
| Cash from Investing | 0.06 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Lui Darren | 14.50 | 18.64 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 994 | 9,011 | 11.03 | |
| 11,531 | 39,337 | 29.31 | |
| 4,675 | 11,461 | 40.79 | |
| 6,012 | 21,760 | 27.63 | |
| 9,027 | 44,687 | 20.20 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALZN – Alzamend Neuro, Inc. | ANEB – Anebulo Pharmaceuticals, Inc. |
| ANIX – Anixa Biosciences, Inc. | APRE – Aprea Therapeutics, Inc. |
| APVO – Aptevo Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io